Ipilimumab-induced Lung Toxicity: Observational Study

Completed

• Conditions: Metastatic Melanoma
• Interventions: Other: Pulmonary Function

• Registration Number: NCT02755233
• Lead Sponsor: University of Zurich

Brief Summary

Serial spirometries and measurements of CO-diffusion capacity (DLCO) in patients with MM before and during treatment with ipilimumab are performed. A reduction from baseline of forced vital capacity (FVC) of ≥10%, or ≥15% of DLCO was defined clinically meaningful, thus indicative for pulmonary toxicity.

Detailed Description

The aim of this prospective observational study is to determine the prevalence of ipilimumab lung toxicity defined by a significant decline of the diffusing capacity of the lung for carbon monoxide (DLCO) and/or forced vital capacity (FVC) in patients with MM.

Patients aged over 18 years with an established diagnosis of MM who are treated and followed up at the Department of Dermatology are asked to participate in the study after the indication for treatment with ipilimumab is given by the interdisciplinary skin tumorboard conference. After written informed consent is obtained, patients undergo a baseline evaluation (V1) including a medical history, physical examination, laboratory analyses (hemoglobin, leucocytes count, C-reactive protein, and pulmonary function tests (PFTs) with spirometry and measurement of DLCO. Thereafter, the first dose of ipilimumab (3mg/kg) is given intravenously over a period of 90 minutes without premedication. The subsequent three doses of ipilimumab are administered three weekly with analogue dose. Subsequent study visits (V2, V3, V4) including PFTs are scheduled on the same day as ipilimumab is administered. Thus, study visits are thoroughly adapted to the clinical visits, which is given by the administration of ipilimumab (total of four injections each separated by three weeks). In case of new respiratory symptoms during the study period, additional PFTs and a high-resolution computed tomography (HR-CT) of the chest are performed. In case of early study termination during follow-up pulmonary function test values which are already obtained are used for the final analysis.

Study Timeline

• Study Start: 2014-01
• Primary Completion: 2015-12
• Study Completion: 2016-03
• Status Verified: 2016-04
• Study First Submitted: 2016-04-15
• Study First Submitted QC: 2016-04-25
• Last Update Submitted: 2016-04-25
• Study First Posted: 2016-04-28
• Last Update Posted: 2016-04-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 71

Inclusion Criteria

• Established diagnosis of metastatic melanoma

Exclusion Criteria

• Acute pulmonary infection at enrolment

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Pulmonary function	Pulmonary Function	Patients in whom treatment with ipilimumab due to metastatic melanoma is indicated

Primary Outcome Measures

Name	Time	Method
Relative reduction of DLCO of more than 15% from the baseline value during follow-up	9 weeks	A relative reduction of ≥15% from baseline of DLCO was chosen as clinically meaningful, thus indicative of a possible interstitial lung disease as a consequence of ipilimumab induced pulmonary toxicity

Secondary Outcome Measures

Name	Time	Method
Relative reduction of FVC of more than 10% from the baseline value during	9 weeks	A relative reduction of FVC of ≥10% from baseline was chosen as clinically meaningful, thus indicative of a possible interstitial lung disease as a consequence of ipilimumab induced pulmonary toxicity

Trial Locations

Locations (1)

Department of Pulmonology; 🇨🇭 Zurich, Switzerland